Latest From David Wild
Startup financing may be hard to come by, but now is not the time to ask for less cash.
As Bayer moves through a challenging period, business development, licensing and impact investment may help buttress the company’s resilience.
With all signs pointing towards a year ripe with partnering opportunities, four big pharma dealmakers reveal what they are looking for.
Dermatology-focused Almirall S.A. is partnering with Microsoft for generative artificial intelligence capabilities. It is the second generative AI-based collaboration announced by Almirall in several months.
To Jerome Pesenti, the biggest hurdle to integrating generative artificial intelligence into the biopharma industry is accepting that data often knows better than humans.
As it often does, this year's J.P. Morgan Healthcare Conference could set the tone for the rest of the year in biopharma. In Vivo revisits the key questions coming out of the 2024 event.